Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Review

Published on 01 Jul 2025

Curcumin, EGCG and apigenin in cervical cancer: mechanistic insights and therapeutic potential

in Pharmacology of Anti-Cancer Drugs

Abdulaziz Asiri
Bayan T. Bokahri
Sadaf
Alaa Abdulaziz Eisa
Hashim M. Aljohani
Wesam Nofal
Tahreem Kausar
Mohammad Zeeshan Najm

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1592395

223 views

Opinion

Accepted on 30 Jun 2025

The Rho/MRTF-Pirin Axis: A Promising Target for Overcoming Melanoma Drug Resistance

in Pharmacology of Anti-Cancer Drugs

Xiaoyan Chen
Junfeng Zhang
Jiuhu Li
Zhi Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1571933

Mini Review

Accepted on 30 Jun 2025

Advancements in Bladder Cancer Immunotherapy: A Focus on Intravesical Approaches

in Pharmacology of Anti-Cancer Drugs

Xia Tang
Tianlun Yu
Hongxuan Tong
Yufan Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1578146

Original Research

Accepted on 30 Jun 2025

Quercetin inhibits the cAMP/PKA/CREB/glycolysis axis to exert anti-acute lymphoblastic leukemia effects

in Pharmacology of Anti-Cancer Drugs

Qiuling Ma
Wenqing Liu
Yajing Su
Jue Guo
Man Zhang
Jiayuan Guo
Mingxin Liu
Wenbo Dong
Mingwei Li
Bo Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1614973

Original Research

Accepted on 30 Jun 2025

CDFA: calibrated deep feature aggregation for screening synergistic drug combinations

in Pharmacology of Anti-Cancer Drugs

Xiaorui Kang
XIAOYAN LIU
Quan Zou
Tiantian Li
Ximei Luo

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1608832

Systematic Review

Accepted on 30 Jun 2025

Long-term Efficacy of CDK4/6 Inhibitors in Early HR+, HER2-High-Risk Breast Cancer: An Updated Systematic Review and Meta-Analysis

in Pharmacology of Anti-Cancer Drugs

Ying Liu
Jun Su
Ping Wu
Wenjie Lv

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1564437

Original Research

Accepted on 30 Jun 2025

Integrative Genomic Analysis Identifies DPP4 Inhibition as a Modulator of FGF17 and PDGFRA Downregulation and PI3K/Akt Pathway Suppression Leading to Apoptosis

in Pharmacology of Anti-Cancer Drugs

Kiran Kumar Chitluri
Arnold Emerson Isaac

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1606914

Original Research

Accepted on 30 Jun 2025

STAT3 mediates CAF-induced osimertinib resistance via regulating protein secretion in non-small cell lung cancer

in Pharmacology of Anti-Cancer Drugs

Xuchen Fan
Sheng Wu
Honglong Wu
Yingying Huang
Xuhui Tong
Meiling Yu
Zhe Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1546491

Review

Accepted on 30 Jun 2025

Unlocking the Potential of Antibody-drug Conjugates in Cervical Cancer: Emerging Targets and Clinical Trials

in Pharmacology of Anti-Cancer Drugs

Yue Zhang
Yao Ding
Yiran Liao
Jin Shu
Yi Gong

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1636120

Case Report

Published on 30 Jun 2025

Potential interactions between traditional Chinese medicine and osimertinib: a Case Report

in Pharmacology of Anti-Cancer Drugs

Min Zhang
Huiwen Ma
Wanyi Chen
Zhongzhen Yuan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1596913

264 views

Original Research

Published on 30 Jun 2025

Characterization of lysine crotonylation-related lncRNAs for prognostic assessment and immune response in glioma

in Pharmacology of Anti-Cancer Drugs

Miaomiao Song
Juan Xu
Zhonghao Gui
Yun Wu
Feifei Wang
Hongmei Sheng
Xueyong Huang
Junyu Qian
Haotian Qin
Ying Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1573694

219 views

Original Research

Published on 30 Jun 2025

Exploration of M2 macrophage-related biomarkers and a candidate drug for glioblastoma using high-dimensional weighted gene co-expression network analysis

in Pharmacology of Anti-Cancer Drugs

Suyin Feng
Long Zhu
Jinyuan Gu
Kun Kou
Yongtai Liu
Guangmin Zhang
Hua Lu
Honglai Zhang
Runfeng Sun

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1587258

204 views

Brief Research Report

Accepted on 27 Jun 2025

Comparison of associations suggests mainly distinct pools of genetic risk factors contribute to cisplatin-induced hearing loss and hearing difficulty in the general population

in Pharmacology of Anti-Cancer Drugs

Mohammad Shahbazi
Heather E. Wheeler
Xindi Zhang
Robert D. Frisina
Lois B. Travis
M. Eileen Dolan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1577072

307 views

Review

Accepted on 27 Jun 2025

CRISPR/Cas9 Technology in Tumor Research and Drug Development Application Progress and Future Prospects

in Pharmacology of Anti-Cancer Drugs

Weiqiang Zhou
Han Han
Xiaoyan Sun
Xiaoyun Guo
Jiaxin Wen
Xiaoming Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1552741

212 views

Original Research

Published on 27 Jun 2025

Glycyrrhiza uralensis Fisch. suppresses cell migration via ROS and JAK/STAT signalling pathways in Drosophila

in Pharmacology of Anti-Cancer Drugs

Fangfei Zhou
Qingge Lu
Lingyu Kong
Sitong Wang
Haixia Zhang
Meng Zhao
Yue Hu
Fanwu Wu
Chenxi Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1549920

294 views

Original Research

Published on 26 Jun 2025

Galectin-9 treatment is cytotoxic for B cell lymphoma by disrupting autophagy

in Pharmacology of Anti-Cancer Drugs

Lisanne Koll
Harm Jan Lourens
Glenn Marsman
Stan de Haan
Toshiro Niki
Gerwin A. Huls
Edwin Bremer
Valerie R. Wiersma

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1601235

318 views